Apremilast

The European Commission ( EC ) has granted marketing authorisation for Otezla ( Apremilast ), an oral selective inhibitor of...


Since the publication of the European League Against Rheumatism ( EULAR ) recommendations for the pharmacological treatment of psoriatic arthritis...


New findings on Apremilast ( Otezla ), a selective inhibitor of phosphodiesterase 4 ( PDE4 ), from the ESTEEM 1...


The FDA ( Food and Drug Administration ) has approved Otezla ( Apremilast ), a oral selective inhibitor of...


The Food and Drug Administration ( FDA ) has approved Otezla ( Apremilast ), oral, selective inhibitor of phosphodiesterase 4...


Results from additional efficacy and safety analyses of Apremilast ( Otezla ) from the ESTEEM phase III clinical trial program...


Apremilast ( Otezla ) is an oral small-molecule inhibitor of phosphodiesterase 4 ( PDE4 ) specific for cyclic adenosine monophosphate...


Results of the phase III POSTURE study evaluating Apremilast ( Otezla ), the oral, selective inhibitor of phosphodiesterase 4 (...


Celgene has announced results of its long-term phase III study on Apremilast, a targeted inhibitor of phosphodiesterase 4 ( PDE4...


Celgene has announced results of phase II trial ( BCT-001 ) on Apremilast, a oral targeted inhibitor of phosphodiesterase 4...


The statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving Apremilast 30...


Apremilast ( Otezla ), a specific inhibitor of phosphodiesterase 4, modulates pro-inflammatory and anti-inflammatory cytokine production. Apremilast's effect on patient-reported outcomes...


Apremilast ( Otezla ), a small-molecule inhibitor of phosphodiesterase 4, works intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and...